Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$3.65 USD
-0.31 (-7.83%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $3.64 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Revance Therapeutics, Inc. (RVNC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.11 | $25.00 | $8.00 | 231.06% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Revance Therapeutics, Inc. comes to $13.11. The forecasts range from a low of $8.00 to a high of $25.00. The average price target represents an increase of 231.06% from the last closing price of $3.96.
Analyst Price Targets (9 )
Broker Rating
Revance Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.70 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.82 a month ago based on 11 recommendations.
Of the 10 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 60% and 10% of all recommendations. A month ago, Strong Buy made up 54.55%, while Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RVNC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.70 | 1.82 | 1.82 | 1.82 | 1.82 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
5/10/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
3/1/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
2/29/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
2/29/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.70 |
ABR (Last week) | 1.82 |
# of Recs in ABR | 10 |
Average Target Price | $13.11 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 252 |
Current Quarter EPS Est: | -0.48 |